Prudential PLC Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Prudential PLC acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 33,773 shares of the biopharmaceutical company’s stock, valued at approximately $1,248,000.

Other institutional investors have also added to or reduced their stakes in the company. Principal Securities Inc. bought a new position in Halozyme Therapeutics in the 4th quarter valued at $34,000. First Horizon Advisors Inc. raised its position in shares of Halozyme Therapeutics by 24.5% in the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 293 shares in the last quarter. Parkside Financial Bank & Trust bought a new stake in Halozyme Therapeutics during the fourth quarter valued at $64,000. Headlands Technologies LLC grew its position in Halozyme Therapeutics by 1,068.2% during the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 1,613 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its stake in Halozyme Therapeutics by 22.4% in the 4th quarter. Quadrant Capital Group LLC now owns 3,414 shares of the biopharmaceutical company’s stock worth $126,000 after acquiring an additional 624 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $45.38, for a total transaction of $453,800.00. Following the completion of the sale, the senior vice president now directly owns 168,176 shares in the company, valued at approximately $7,631,826.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 2.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on HALO. raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. JMP Securities decreased their price target on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 8th. TD Cowen initiated coverage on shares of Halozyme Therapeutics in a report on Thursday, February 29th. They set an “outperform” rating and a $54.00 price objective for the company. Wells Fargo & Company upped their target price on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Piper Sandler downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the company from $48.00 to $51.00 in a research report on Friday. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.13.

Read Our Latest Stock Analysis on Halozyme Therapeutics

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $51.16 on Tuesday. The company has a 50-day simple moving average of $42.08 and a two-hundred day simple moving average of $39.39. Halozyme Therapeutics, Inc. has a 12-month low of $32.78 and a 12-month high of $53.00. The firm has a market cap of $6.51 billion, a price-to-earnings ratio of 21.14, a PEG ratio of 0.57 and a beta of 1.28. The company has a quick ratio of 5.36, a current ratio of 6.64 and a debt-to-equity ratio of 8.44.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The company had revenue of $195.88 million during the quarter, compared to analysts’ expectations of $201.72 million. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 3.44 EPS for the current year.

Halozyme Therapeutics Profile

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Read More

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with's FREE daily email newsletter.